Spatial navigation questionnaires as a supportive diagnostic tool in early Alzheimer's disease.
Clinical neuroscience
Disease
Neuroscience
Journal
iScience
ISSN: 2589-0042
Titre abrégé: iScience
Pays: United States
ID NLM: 101724038
Informations de publication
Date de publication:
21 Jun 2024
21 Jun 2024
Historique:
received:
10
12
2023
revised:
14
03
2024
accepted:
24
04
2024
medline:
23
5
2024
pubmed:
23
5
2024
entrez:
23
5
2024
Statut:
epublish
Résumé
Impaired spatial navigation is early marker of Alzheimer's disease (AD). We examined ability of self- and informant-reported navigation questionnaires to discriminate between clinically and biomarker-defined participants, and associations of questionnaires with navigation performance, regional brain atrophy, AD biomarkers, and biomarker status. 262 participants (cognitively normal, with subjective cognitive decline, amnestic mild cognitive impairment [aMCI], and mild dementia) and their informants completed three navigation questionnaires. Navigation performance, magnetic resonance imaging volume/thickness of AD-related brain regions, and AD biomarkers were measured. Informant-reported questionnaires distinguished between cognitively normal and impaired participants, and amyloid-β positive and negative aMCI. Lower scores were associated with worse navigation performance, greater atrophy in AD-related brain regions, and amyloid-β status. Self-reported questionnaire scores did not distinguish between the groups and were weakly associated with navigation performance. Other associations were not significant. Informant-reported navigation questionnaires may be a screening tool for early AD reflecting atrophy of AD-related brain regions and AD pathology.
Identifiants
pubmed: 38779476
doi: 10.1016/j.isci.2024.109832
pii: S2589-0042(24)01054-X
pmc: PMC11108981
doi:
Types de publication
Journal Article
Langues
eng
Pagination
109832Informations de copyright
© 2024 The Author(s).
Déclaration de conflit d'intérêts
J.H. is a medical advisor at Neurona lab, Terrapino mobile app, consulted for Eisai, Eli Lilly, Biogen, Schwabe, and holds stock options in Alzheon.